BioLight Life Sciences Ltd.

General Information

(NOTE: A Public offering: BioLight’s ordinary shares have traded on the Tel Aviv Stock Exchange since December 2005.)

We are an emerging global ophthalmic company focused on the discovery, development and commercialization of products and product candidates which address ophthalmic conditions, including glaucoma, DES, and AMD. Our current products and product candidates are designed to address a number of significant unmet medical needs of large and growing patient populations related to these ophthalmic conditions, by reducing patient non-compliance with drug therapy administration, improving efficacy and safety of treatment, offering better diagnosis and optimizing delivery of medications.

Employees: 15
Founded: 2005
Contact Information
Address Kiryat Atidim Building 3, Tel Aviv, 6158101, Israel
Phone Number 972-73-2753400
Web Address
View Prospectus: BioLight Life Sciences Ltd.
Financial Information
Market Cap $26.6mil
Revenues $0.4 mil (last 12 months)
Net Income $-7.5 mil (last 12 months)
IPO Profile
Symbol BOLT
Exchange NASDAQ
Shares (millions): 2.1
Price range $4.60 - $6.60
Est. $ Volume $12.0 mil
Manager / Joint Managers Feltl and Company/ Rodman & Renshaw a unit of H.C. Wainwright & Co.
CO-Managers -
Expected To Trade: 3/14/2016
Status: Postponed
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change